1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Infections
  5. COVID-19

COVID-19 rapid guideline: delivery of systemic anticancer treatments

NICE guideline [NG161] Published: 20 March 2020 Last updated: 11 August 2022

  • Guidance
  • Tools and resources
  • Evidence
  • History

Research recommendation(s) from an individual piece of guidance

Guidance:
COVID-19 rapid guideline: delivery of systemic anticancer treatments
Date issued:
20 March 2020

Research recommendations coming out of this guidance

  • Risk of systemic anticancer treatment in people with cancer and COVID-19: Are patients with cancer and COVID-19 who are receiving/have recently received systemic anticancer treatment (SACT) (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of severe COVID-19 illness or death?

  • Duration of risk of systemic anticancer treatment in people with cancer and COVID-19: Are people who have had SACT recently (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of poor outcomes from COVID-19 compared with those who had SACT less recently?